Results from the INMUNOSUN-SOGUG Trial: a Prospective Phase II Study of Sunitinib As a Second-Line Therapy in Patients with Metastatic Renal Cell Carcinoma after Immune Checkpoint-Based Combination Therapy
ESMO open（2022）
关键词
metastatic renal carcinoma,immune checkpoint inhibitors,second-line treatment,sunitinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要